Trial Profile

A PHASE III, RANDOMIZED, MULTICENTERIC, CONTROLLED STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF BBILs TYPHOID Vi CAPSULAR POLYSACCHARIDE-TETANUS TOXOID PROTEIN CONJUGATE VACCINE VS REFERENCE VACCINE IN HEALTHY SUBJECTS - Typbar TCV [EXTENSION OF 700207393]

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Typhoid vaccine Vi conjugate (Primary) ; Typhoid vaccine Vi-polysaccharide
Indications Typhoid
Focus Pharmacodynamics
Sponsors Bharat Biotech

18 Oct 2021 Status changed from recruiting to completed, as per India Clinical Trials Register record.
05 Oct 2021 Results from CTRI2014-01-004341 and CTRI2011-08-001957, for follow on monitoring of serum IgG Vi antibody titers at 3, 5, and 7 years after initial vaccination of infants/toddlers, including those who did, or did not, receive a booster vaccination 720 days post primary immunization, published in the Vaccine
19 Feb 2014 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com